The author describes the case of a 68-year-old woman who expe rienced severe symptoms of Meniere 's syndrome. Ultrasonography ofthe neck detected a clot in the left internal j ugular vein. The patient was hospitali zed and anticoagulated, and her symp toms soon resolved. The author speculates that the clot-indu ced hemodynamic changes led to venous insufficiency in the vein of the paravestibular canaliculus and ultimately caused the patient' s symptoms. The blood work-up revealed that the patient had an elevatedfasting homocysteine level, which is a known risk f actor f or thrombus fo rmation.
Introduction
Hyperhomo cysteinemia is a risk factor for both arterial and venous thromb osis. In this article , the author describes the case of a patient who developed incapacitating Meniere' s symptom complex. The work-up revealed a left internal jugular vein thrombosis, and it was later found that the patient had hyperhomocysteinemia. The author postulates that the hyperhomocysteinemia predi sposed this patient to clot formation in the left internal jugular vein and this in turn led to the development of the Meniere's symptoms. Once the patient was anticoagulated , her symptoms resolved.
Case report
A 68-year-old white wo man had been initi ally treated by the author for vertigo, left-sided tinnitus, and left-sided aural fullness . During her epis odes of verti go, she exp erienced nausea, vomiting, and decreased hearing in her left ear. She had no hist ory of traum a or instrumentation to her head and neck . Afte r conserv ative managem ent with mecli zine and methylprednisolon e failed to allev iate her symptoms , she was refe rred to an otol aryngologist.
During the initial referral co nsultation, findin gs on a Dr. Scaramella is a family physician in private practice in Chicago . Reprint requests: John G. Scarame lla, MD, 4742 N. Austin, Chicago , IL 60630. Phone: (773) 202-8034; fax: (773) 202-8 147 . 856 complete head and neck eva luation were wit hin normal limits . Audiometr y dem onstrated a low-frequency sensorineural hearing loss on the left and some redu ction in the patient' s speech discrimination scores (84 % on the left ; 100% on the rig ht). She was diagnosed with Meniere 's symptom complex and give n dietary instructions. Despite these measures, the Meniere' s sy mptoms incapacitated the pat ient to the point where she was unable to work. She next und erwent magnetic resonance imagin g (MRI) of the brain and magnetic reson ance angiography (MRA) of the neck . Find ings on MRI were esse ntially unremarkable, but MRA revealed a possible 60 to 70% stenosis of the right internal carotid artery. Th e patient was then sent for a Doppl er ultrasound study of the carotids. Ultr asonograph y did not detect any hemodynamic stenosis , but it did show a thr ombus in the left proximal internal jugular vein (figure I). Her prot ein C and S levels were within normal limits. The patient was hospitalized and anticoag ulated with I mg/kg of enoxaparin subcutaneously every 12 hours. She was the n started on warfarin to achi eve an interna tional normali zed ratio betwe en 2.0 and 2.5. Onc e the patient was anticoag ulated, her Meniere' s symptoms reso lved.
Durin g warfarin antic oagulation, a hematologic evaluation yield ed norm al values for antithro mbin III, lupu s anticoagulants, prothrombin gene mut ations, antinuclear antib odies, and anticar diolipin antibodies. However, her fasting homo cystein e level was elevated at 20.3 um ol/L (range of norm al: 4.5 to 12.4). She was started on I mgt day of folic acid and a once-dai ly mult ivitam in. She was maintained on warfarin for 6 months and then swi tched to aspirin at 325 mg/day.
A follow-up ultrasound approxi mately 2 month s afte r the start of antic oa gulation showed no clot in the left intern al ju gular vein (figure 2). An ultrasound performed approximately 3 month s after warfarin was discont inued again did not dem onstr ate a left internal ju gular vein clot (figure 3). The patient remained free of her Meniere' s symptoms durin g her 6 months on antico agulation, and she remained symptom-free on a reg imen of I aspirin per day at 15 month s of follow -up. ZITHRDMAX' , at therecommended dose. shouldnot be relieduponto treat syphilis. Antimicrobial agentsusedin highdoses forshort periods of time to treatnon-gonococcal urethri tis may mask or delaythesymptoms of incubating syphilis. All patients with sexually-transmittedureth ritis orcervicitis should have a serologi c testforsyphilis and appropriateculturesfor gonorrhea perf ormed at thetime of diagnosis. Appropriate anti microbial therapyand foll ow-up tests lorthese diseases should be initiatedif infectionis confirmed.
Appropriatecultureandsusceptibility testsshoul d be performed before treatment todetermine thecausative' organismandits susceptibility to azi thromscinTherapywith ZITHRDMAX' maybe initiated beforeresults of these tests areknown; oncethe results become available. antimicrobial therapyshould be adjusted accordingly.
CONTRAINOICATIONS
ZITHA DMAX' is contraindicated in pat ients with known hyp ersensitivity to azithrom ycin. eryt hromycin orany macrolide antibiotic. WARNINGS Ser iousallergic reactions. including angioedema. anaphylaxis.anddermatologic reactionsincluding Stevens JohnsonSyndrome and toxic epidermal necrolysis hav e been reported rarelyin pat ientsonazithromycin therapy. Althoughrare. fatalitieshave been repcrted. Isee CO NTRAINDICATIONS.I Despite initiallysuccessful symptomatic treatment of the allergi c symptoms.when symptomatic therapywas disconti nued. theallergic symptoms recurred soon thereafter in somepatients without further azithromycin exposure. Thesepat ient s required prolonged peri odsof obs ervationandsymptomatic treatment. The relationship of these episodes to the long tissue hal f-life ofazithromycin and subsequentprol ongedexposure toantigenis unknownat present.
If an allergic reaction occurs. thedrugshouldbe discontinued andappropriate therapyshould be instituted. Ph ysicians should be aware thaireappearance of the allergic symptoms mayocc ur when symptomatic therapy is disc onti nued.
In the treatment of pneumonia. azithromycin has only been show n to be safe and effective in the treatment of commun ity-acquired pneumonia dueto Chlamydia pneumoniae. Haemophilus influenzae. Mycoplasma pneumoni ae. or Streptococcus pneumoniaein patients appropriate for oral therapy. Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe ill ness or risk factors such as anyof the followi ng: patients wit h cystic fibrosis. patients with nosocomiall y acquired infections, patients with known or suspected bacteremia. patients requiring hospitalization. elderly or debilitated patients. or patients with significant underlying health problemsthat may compromise their ability to respondto their illn ess (including immunodeficiency or functional asptenlal.
Pseudomembranous colit is has been reported with nearly all antibacterial agents and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients w ho present w ith diarrhea subsequent to the administration of antibacterial agents.
Treatment with antibacterial agentsaltersthenormal floraof the colon and may permit overgrowthof clost ridia.
Studies indicate thata toxinproduced byClostridiumdifficileis a prim arycause of "antibiotic-associ ated colitis."
Afterthediagnosis of pseudomembranous colitis has been est ablished.therapeutic measures should beinitiated. Mild cases of pseudomembranouscolit is usually respondto discontinuationof thedrug alone. In moderate to severe cases.con sideration should begivento managementwith fluids and electrolytes.protein supplementat ion. and treatment with an antibacterial drugclinically effective against Cl ostridiumdifficilecolitis.
PRECAUTIONS
General: Because azithromycin is princ ipally elimi nated viathe liver. cautionshould be exercisedwhen azi thromycin is administered10 patients with impairedhepatic function. Due to the limiteddata in subjects with GFR <10mUmin. caution should be exercised when prescribing azithromycin in these pat ients.
The following adverseevents have been reportedwith macrolide products: ventricular arrhythmias. inclu ding ventr iculartachycardia and torsade depointes . in indivi duals withprolong edOT interval s.
There has beena spontaneousreport fromthepost-marketing experience of a patient with previoushistory of arrhyt hmiaswhoexperienced torsade depointes and subsequentmyocardial infarctionfollowinga course of azithromyci n therapy. Information for Patients: ZITHROMAX$tablets canbetaken withor without food.
Pat ients should alsobe cautionednot 10 takealuminum-and maqnesium-containinq anta cidsand azithromycin simultaneousl y.
The patientshould bedirectedto discontinueazit hrornyein imm edialely andcont acta phy si cian if anysignsof an allergic reactionoccur. Drug Interactions: Co-administration of nelfinavirat steady-state with a single oral doseof azit hromycin resulted in increased azithromycin serum concentrat ions. Althougha dose adjustment of azithromycin is not reco mmended whenadministeredin combination with nelfinavir, close monitoring for knownsideeffects of azithmmycin . such as liver enzyme abnormalitiesand hearing impairment, iswarranted. (See ADVER SEREACTIO NS.)
Azilhromycin didnotaffect the prothrom bin timeresponse toa single dose of warfarin. However, prudent medical practice dictatescaref ul moni toring of prothrombin time in all patients treatedwith azithro mycin andwarfarin concomitantly. Co ncurrent useof macrolidesandwarfarin in clinical practice hasbeen associated with increased anticoagulant effects.
Drug interactionstudieswere perf ormed with azithromycin and ather drugslikely to be co-administered. Whenusedin therapeuticdoses. azithromycin had a modest effect on the pharmacokinet icsof atcrvastatin. carbamazepine . cetirizine. dida ncsine . efavirenz. fluconaz ole. indinavir, midazolam. rifabutin. sildenafil, theoph ylline (intravenous and oral).mazolam, trimethopr im/sulfamethoxazole or zidowdine. Co-administration with etavirenz or fluconazole had a modest effect onthe pharma cokinetics of azi thromycin.No dosage adjustment of either drug is recommendedwhen azi rbromscinis coadministeredwith any 01the above agents.
Interactionswith thedrugs listedbelow havenotbeen reported in clinical trialswith azithro mycin; however. no specific drug interaction studieshave been performed to evaluatepote ntial drug-drug interaction.Nonetheless. they have beenobserved with macrolide products. Unt il further dataare developed regarding drug interactionswhen azi thromycin and these drugs are usedconcomitantly. careful monitoring of patients isadvised:
Oi goxin-elevated digoxin concentrations. Er gotamine or dihydroergotami ne-acute ergottoxicity characterized by severeperipheral vasospasm and dysesthesia.
Ierfenadine. cvclosporine, hexobarbital andphenyt oin concentrations. Nursing Mothers: It is not known whether azithromycin isexcreted in human milk.Because many drugs areexcreted in human milk. cau tionshoul d be exe rcisedwhen azi thromycin is administered to a nursingwoman. Studies evaluating the use of repeated coursesof therapy have nol been conducted. Geriatric Use:Pharmacokinetic parameters in older vol unteers 1 65-85years oldlwere similar to those in younger volunteers11 8-40 years old)for the5-day therapeutic regi men. Dosage adjust mentdoesnot appear to benecessary for older patientswith normal renal andhepati c functionreceivingtreatment with this dosage regimen.
In multiple-doseclinicaltrials of oral anthromjcin. 9%of patients were at least 65 years of age{458/49491 and 3%of patients(144/49491 wereat least 75 years of age. No over all differencesin safetyoreffectivenesswere obse rved betweenthesesub jectsandyounger sub jects.andother reported clinical experience has not identified differences in response between theelderly andyounger patients. butgreater sensitivityof some olde r individuals cannot be ruled out.
ZITHROMAX' 250 mg tablets contain 0.9 mgof sodiumper tablet.ZITHROMAX&500 mgtablets contain1.8 mgof sodium pertablet.
ADVERSE REACTIONS In clinicaltrials. most of thereponed sideeffects were mild to moderate in severity andwere reversibleupon discontinuationof the drug. Potentially serious sideeffects of angioedema and chclestati c jaundicewerereport ed rarely. Approximately 0.7%of the pati ents(adults and children)from the5·day mul tiple-dose clinical trialsdisc ontinued ZITHROMAX&(azithrumycinl therapy because of treatment-related side effects.Inadults gi ven 500 mg/day for 3 days, the discontinuationratedue totreatment-related side effects was0.4%. Inclinical trial s inchildrengiven 30 mg/kg.either asa sing le dose or over 3 days. discontinuation from the trials dueto treat ment-relatedsideeffects wasapproximately 1%.ISee DOSAGE ANDADMINISTRATION .) Most of the side effects leadingtodiscontinuation wererelatedto the gastrointestinal tract . e.g., nausea. vomiting. diarrhea, orabdominal pain. Clinical: Adults: Multiple·dose regimens: Overall. themost common treetment-related sideeffects in adult patients receiving multiple-doseregimens of ZJTHROMAX--were relat edtothegastrointestinal systemwith diarrhea/loose stools(4-5%1. nausea13%)andabdominalpain 12-3%1beingthemost frequently reported.
Noothertreatment-relatedsideeffectsoccurred in pat ients onthemul tiple-dose regimens of ZITHROMAX&with a frequencygreaterthan 1%. Sideeffects that occurred with a frequency of 1%or less included thefollowing: Cardiovascular: Palpitations . chest pain. Gastrointestinal: Dyspepsia. flatulence, vomiting. melena andcholestatic jaundice. Genitourinary: Monilia. vagi nitis andnephritis. Nervous System: Dizzines s. headache. vertigo and somnolence. General: Fatigue. Allergic: Rash. pruritus. photosensitivity and angioedema_ Single 1-gramdos e regimefT. Overall, the most commonsi de effects in pat ient s receiving a singl e-dose regimenof 1 gramof ZITHROM AX&were relat edto the gastr oint estinalsys tem andweremorefrequentlyreported than in pat ients receiving the multiple-doseregimen.
Sideeffec ts that occurred in patients on the single one-gram dosingregimenof Z1THROMAX" with a frequencyof 1%orgreater included diarrhea/loose stools (7%1. nau sea15 %1. abdominal pai n15%1. vomi ting(2%I,dys pepsi all %1 andvaginitis(1%). Single2-gramdose regimen: Overall, the mostcommonside effects in pat ients receiving a single 2-gram dose of ZITHADMAX· wererelated to thegastrointestinal sys tem. Side effects that occurredin pat ientsin this studywitha frequencyof l %orgreater incl udednausea 118%1 . diarrhea/loose stools(14%).vomiting17%1. abdominal pain (7%1. vagini tis{2%1. dyspepsia11%1and diu iness (1%}.The majority of these comp laintswere mild in nature. Post-Marketing Experience: Adverseevents report edwith azi thromycin duringthe post-marketing per iodin adult and/or pediatric pat ients for whicha causalrelationship may not beestablished include:
Allergic: Arthralgia.ede ma. urticariaandangioedema. Cardiovascular: Arrhyt hmi asinclu ding ventr icular tachycardia and hypotension. Gastrointestinal: Anorexia.constipation. dyspepsi a. flatulence. vomiting/diarrhea rarely resulting in dehydration. pseudomembranouscolitis. pancreatitis. oral candidiasisandrare reports of tongue discoloration. General: Asthenia. paresthesi a. fatigue. malaise andanaphylaxis(rarel y fatal). Genitourinary: Interstitial nephritisandacut e renal failure andvaginitis. Hematopoietic: Thrombocyt openia. LiverIBili ary: Abn ormalliverfunction incl uding hepatitisandcholestat ic jaundice.aswell asrare cases of hepatic necrosisand hepatic failure. someof whichhave resulted indeath. Nervous System:Convu lsi ons.dizziness/vertigo, headache. somnolence. hyperactivity. nervousness. agitation andsyncope . Psychiatric: Aggressive reactionand anxiety. Skin/Appendages: Pruri tus,rarely seri ousskin reactions includingerythema multilorme. StevensJohnson Syndromeandtoxi c epidermal necrolysis. Special Senses: Hearing disturbancesincludinghearing loss, deafness and/or tinni tus and rare reports of taste perversion. l aboratory Abnormalities: Adults: Clinically signif icant abnorma lities(irrespectiveof drugrel ationshi p)occ urring during the clinical trials were reportedasfollows: withan incidence of greater than 1%: decrease d hemoglobin. hematocrit, lymphocyt esand blood glucose;elevat edserum creatinephosphokinase. potassium, ALTISGPTI. GGT . andAST(SGOTI. BUN. creatini ne. bloodglucose. plateletcount. eosinophi ls; with an incidence of less than1%: leukopenia. neutropenia. decreasedplatelet count. elevated seru m alkaline phosphatase. bilirubin. LDH and phosphate. The majorityof subj ectswith elevated serum creatininealsohad abnormal valu esat bas eline.
Whenfollow-upwas provided. changes in labor atorytests appeared to be reversible. In multiple-doseclinical trialsinvolving more than 4500patients. three pat ients discontinuedtherapy becauseof treatment-related liver enzyme abnormalitiesand one because of a renal functi on abnormality.
DOSAGE ANDADMINISTRATION ISee INDICATIONS ANDUSAGE.)
Adults: The recommended dose of ZITHAOMAXl forthe treatment ofcommunity-ac quired pneumonia ofmild severity. pharyn gitis/tonsill itis(assecood-line therapyl , anduncomplicatedskin and skin structure infectionsdue to the indicated organisms is: 500 mgasa single-d ose 00 thefirst day fotlO\ ved by250mgonce daily onDays2 through 5. The recommendeddoseof ZITHADMAXl for the treatment ofmild tomoderateacutebacteri al exacerbationsofchr onic obstructivepul monary disease is:either 500mgperday for3 days or 500 mgasa singl e dose on thefirstdayfoll owed by250 mgonce daily onOays 2 thr ough 5.
ZITHROMAX tablets can be taken with or without food. The recommended doseof ZITHAOMAX" forthetreatment of genital ulce r disease dueto Haemophilusducreyi (chancroid).non-gonoc occal urethritis andcervicitis due10 Chlamyd ia trac homatis is: a single 1gram (10 00mgl dose of2ITHROMAX' .
The recommendeddoseof ZITHAOMAX" forthetreatment ofurethritis and cervicitis dueto Neisseria gonorrhoeaeis a single 2 gram 12000mgl dose of ZITHROMAX' .
Renal Insufficiency: Nodosage adjustment is recommended for subjects withrenal impairment (GFA ::: 80 mUminl. The mean A U~' a wassimi larin subjects with GFR 10-80mUmin compared to subjects with normal renal lunction. whereas it increased 35%in subjects with GFR<10 mUmin compared to sub jectswith normal renal function, Caution should be exercised when azilhromycin is administere d to subjectswithsev ererenal impairment Hepatic Insufficiency:
The pharmacokinetics of azi thromycin in sub jectswith hepatic impairment have not been established. Nodose adjustment recommendations canbemadein pat ientswith impaired hepat ic function.
No dosage adjustment is recommended based onage or gender.
Formore detai ledprofessional information please referto the full prescribing information. 
Discussion
Hyperhomocysteinemia can predi spose patients to deep vein thrombosis; in this case, the patient' s left internal jugular vein was affected. The author postulates that the clot in the left internal ju gular vein caused an increase in venous pre ssure that resulted in venous insufficiency in the vestibular organs. This in turn led to endolymphatic hydrops and the subsequent development of Meni ere' s symptom complex. The vein of the paravestibular canaliculus (VPVC) runs parallel to the endolymphatic duct and drains the major portion of the semicircular canals and part of the utricle. The mean width of the paravestibula r canaliculus is 0.12 mm.' The VPVC receives several veins from the endolymphatic sac and drains into the inferior petro sal sinus or directly into the jugular bulb ( figure 4) .
Some research has shown that there are certain variations in the pattern of venous drainage of the vestibul ar organs. Mazzoni demon strated that in a certain percent- age of human temporal bone s, one or two of the vestibular veins drain throu gh the VPVC rather than servin g as tributaries of the inferior cochlear vein.? Gussen suggested that in these tempo ral bones, venou s insufficiency in the VPVC might produce endolymphatic hydrop s.' Gussen postulated that increased venou s pressure and insufficiency of the vestibular organ s could repre sent the common endpoint of many of the entiti es known to cause Meniere ' s disease, althou gh the exact mechan ism of increased vestibular venous pressure may differ in each circumstance.
The author postulates that the clot in the left internal jugular vein in this patient altered the blood flow dynamics, which led to increased venou s pressure and the resultant venous insuffici ency in the VPVC. It is known that the VPVC can drain directly into the jugular bulb. In this patient, the resultant hemod ynamic alteration occurring in the leftjugular bulb may have disturbed the venou s drainage of the endolymphatic duct and/or sac, thereby produ cing end olymphatic hydrop s. In fact, in an article on the surgical lowering of the high ju gular bulb in~he treatment of 13 patients with Meni ere ' s disease and pulsatile tinnitu s, Couloigner et al postulat ed that the symptoms in these patients were cau sed by compression of venous drainage of the endolymphatic duct and/or sac by the high ju gular bulb.' After they surgically lowered the jugul ar bulb , the symptoms improved, thus adding credence to the impo rtance of venou s drainage of the vestibular organs through the VPVc. In the case described here , the effect of the clot in the left internal jugular vein was similar to the effect of a high ju gular bulb with respect to the way it altered blood flow dynamic s.
The hematologic work-up in the patient described here revealed that she had hyperhomocysteinemia, which increases the risk of clot formation . Hyperhomocysteinemia occurs as a consequence of either (1) the inability of homocysteine to remeth ylate to methionine or (2) the transsulfuration of methi onine to cysteine. Folic acid and vitamins B 6 and B I2 are import ant in the proce sses of remeth ylation and tran s-sulfuration (figure 5). Clot formation is apt to occur in the pre sence of one or more of Virchow ' s triad (inti-
